Conditions:  Pancreatic Cancer;  Breast Cancer;  Gastric Cancer;  Non Small Cell Lung Cancer;  Cervical Cancer;  Endocervical Cancer;  Squamous Cell Carcinoma of Head and Neck;  Bladder Urothelial Cancer;  Colorectal Cancer;  Esophageal Cancer;  Ovarian Cancer;  Renal Cell Carcinoma;  Prostate Cancer;  Melanoma;  Mesothelioma;  Cholangiocarcinoma
Interventions: Â Drug:Â NGM438; Â Drug:Â Pembrolizumab
Sponsor:  NGM Biopharmaceuticals, Inc
**RECRUITING NOW**
Interventions: Â Drug:Â NGM438; Â Drug:Â Pembrolizumab
Sponsor:  NGM Biopharmaceuticals, Inc
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
